New Journey Health Technology Group (SHE:002219) said its chair, Lin Yanglin, is under investigation by Taiyuan authorities for unrelated personal matters.
Director Xu Minggui will serve as acting chair during the probe, according to a Monday filing with the Shenzhen bourse.
The healthcare company said there are no material adverse effects on its business operations.
Shares of New Journey Health Technology Group closed 4% lower Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments